Micro-Sphere increases capsule filling capacity8 Oct 2018
The MG2 Tekna increases the CDMO’s manufacturing capacity to up to 500 million capsules per year.
Switzerland-based CDMO Micro-Sphere has announced that its MG2 Tekna capsule filling machine is now online, adding further strength to its offering in encapsulation for inhalation products.
Situated in a dedicated cleanroom at Micro-Sphere’s recently expanded facility near Lugano in Ticino, the MG2 Tekna is in an area of controlled relative humidity of 20% (rH 20% +/- 5%), has a production capability of 110,000 cps/hour and increases the CDMO’s manufacturing capacity to up to 500 million capsules per year.
Alongside the MG2 Tekna machine the company has also invested in a MultiNETT, a net weight control system that monitors and reports the net weight of each dosed capsule. The MultiNETT system employs capacitive tomography to guarantee accuracy and precision and rejects all capsules it deems out of specification.
Michael Grassberger has recently been promoted to managing director at Micro-Sphere and is spearheading the company’s plans to increase its client portfolio with its greater capacity and improved services.
He said: “Micro-Sphere has always strived to offer the best possible service to our customers. This investment is the result of increasing client demand for encapsulation services and our drive to offer customers real commercial benefits.
“This new machinery will offer high-quality products, reduced production times, detailed batch reporting and, ultimately, cost savings.
“Added to our existing Harro Höfliger drum dosing equipment the new MG2 Tekna dosator system means we are the only CDMO in the world to offer these two important commercial size filling techniques under one roof.”
This latest announcement is the final step in Micro-Sphere’s 21 million CHF (€19 million) investment plan to expand its GMP manufacturing capabilities and comes as the company celebrates its 20th year in business.
Michael added: “In all of its 20 years our company has been committed to strengthening our niche capabilities in spray drying and inhalables. The expansion has seen a significant investment of time and resource and now enables us to move forward with our planned growth and hopefully garner success for at least another 20 years.”
SIRIO Pharma opens multimillion gummy production plant
18 Oct 2018
The new ‘Centre of Excellence’ already boasts one of the world’s most advanced gummy production line designed to meet demand from global markets.Read more
Tjoapack and Veratrak launch EPOCH initiative
17 Oct 2018
The virtual platform is designed to allow the healthcare industry to effectively research and explore new technologies that will help to shape the future of the pharmaceutical supply chain.Read more
Cambrex invests $3m to upgrade generic API manufacturing facilities at Milan site
16 Oct 2018
The investment increases the overall capacity and capabilities of the facility, and its flexibility.Read more
Particle Sciences to open new commercial facility
15 Oct 2018
New facility will offer customers the full range of services from development through to commercial-scale manufacturingRead more
Generics companies to move away from "little white pills"
14 Oct 2018
Accepting more complexity and risk is key for those generics companies seeking competitive differentiation by diversifying their product portfolios.Read more
Pharma manufacturers warned to invest in continuous manufacturing
11 Oct 2018
CMOs hit by reduced volumes of opioid manufacturing from DEA quota changes, but cannabis sales to ignite.Read more
New portable and ready-to-use upper respiratory drug delivery solution
11 Oct 2018
PureHale is valuable to pharmaceutical partners seeking a system that can carry a range of formulations and comes in various container sizes.Read more
CPhI Worldwide announces the winners of the 15th Pharma Awards
10 Oct 2018
17 winners chosen from over 250 entries, with Nanobiotix winning both ‘CEO‘ and ‘Pharma Company of the Year’ categories.Read more
CMOs to benefit from double digit approvals for ADCs in the next 3 years
9 Oct 2018
Therapeutic ADC market expected to reach $4 billion by 2023.Read more
Symbiosis secures FDA viral vector process approval
5 Oct 2018
Strengthens the CDMO's position as a centre of excellence as part of the viral vector drug development supply chain.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation